By suppressing the expression of SLP2 by inhibiting the nuclear factor κB/matrix metalloproteinase-9 (NF-κB/MMP9) pathway, the migration ability of glioma cells can be reduced substantially [33]. The gene discussed is STOML2; the disease is central nervous system cancer.